This research highlight summarizes work by Blizard et al. on non-invasive measurement of mRNA vaccine antigen expression in vivo. Its relevance to mRNA delivery research is that it separates the location of a delivery vehicle or mRNA molecule from the appearance and persistence of the translated protein product. The source is a research highlight rather than the full original research article, so detailed formulation, dosing, and analytical methods are not available in the supplied text.
Research Question
The study addressed whether positron emission tomography (PET) could quantify where and for how long an mRNA-encoded vaccine antigen is expressed in the body. The highlight contrasts this objective with imaging delivery vehicles such as lipid nanoparticles or the mRNA itself, which does not directly provide a quantitative, spatiotemporal measure of the protein produced from the mRNA.
The reporter was Escherichia coli dihydrofolate reductase (eDHFR), described as an 18 kDa protein tag. When encoded together with the antigen, eDHFR and the antigen are expressed in a 1:1 ratio for as long as the genetic material remains in the cell, according to the highlighted explanation. This makes the reporter relevant to functional expression, not merely to labeled-RNA uptake.
Study Design and Methods
The PET system used trimethoprim (TMP) as a radiotracer. After TMP administration, the tracer circulates through the blood and major organs, selectively binds the eDHFR tag, and unbound tracer is rapidly eliminated, according to the source text. Whole-body PET imaging was then used to assess the spatial and temporal pattern of TMP accumulation as a proxy for eDHFR-tagged antigen expression.
The researchers tested the system with an approved COVID-19 mRNA vaccine design by fusing eDHFR to mRNA encoding the delta-furin-cleavage-site, proline-stabilized SARS-CoV-2 spike glycoprotein, identified in the supplied text as S2PΔf mRNA. The highlighted experiments included female mice and male non-human primates. The text does not report the ionizable lipid, PEG lipid, particle composition, encapsulation efficiency, particle size, administration dose, or administration route. It therefore does not establish use of ALC-0315 or support a comparison among lipid nanoparticle formulations.
Main Findings
Whole-body PET imaging showed transient antigen expression at the injection site and in draining lymph nodes. The highlighted signal disappeared within 7–20 days. The central finding is methodological: TMP accumulation provided a way to monitor the biodistribution and persistence of the translated antigen in vivo, rather than only the distribution of a carrier or the presence of RNA.
Interpretation: For mRNA delivery studies, this reporter can help distinguish successful delivery followed by translation from particle localization or RNA uptake alone. The source does not state that every labeled-RNA molecule was translated, nor does it present separate uptake and protein-output measurements. Accordingly, the PET readout should be described as an indirect measurement of eDHFR-tagged antigen expression through TMP binding, not as a direct measurement of nanoparticle uptake or total intracellular mRNA.
The highlight proposes that quantitative expression mapping could inform dosing decisions and the development of mRNA therapeutics intended for particular tissues. These are stated potential applications, not clinical efficacy findings. The supplied text does not report therapeutic outcomes, organ-targeting optimization, delivery-related tolerability, stability, endosomal escape, or comparative performance against another lipid nanoparticle system.
Limitations
- This source is a research highlight, not the full original research article; detailed experimental procedures and quantitative datasets are not included in the supplied text.
- The text does not identify the delivery vehicle or disclose ionizable-lipid, PEG-lipid, encapsulation, or formulation-comparison data.
- The reporter measures expression of an eDHFR-tagged antigen through TMP binding. It does not by itself establish total mRNA biodistribution, nanoparticle biodistribution, cellular uptake, endosomal escape, or the fraction of delivered mRNA that was translated.
- The reported disappearance of signal within 7–20 days describes the highlighted PET observation in the tested animals; it does not establish a general persistence period for all mRNA vaccines or delivery systems.
- The text reports experiments in female mice and male non-human primates but does not provide enough information to assess sex-related, species-related, formulation-related, or tolerability differences.
Source
In vivo tracking of mRNA vaccine antigen expression. Nature Reviews Bioengineering 3, 269 (April 2025). The supplied highlight identifies the underlying original article as Blizard, G. S. et al., Monitoring mRNA vaccine antigen expression in vivo using PET/CT, Nature Communications 16, 2234 (2025). Detailed claims about formulation and methods should be taken from that original article rather than inferred from this highlight.